Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 29 ... that African-American patients with colorectal cancer were more likely to present with metastatic disease (23.17 percent versus 14.75 percent Caucasians;Keywords: ...
2009 NOV 28 ... for myogenin, MYOD1, and endothelial markers. Rate of local recurrence is 2% to 20%. The metastatic rate is 1%," wrote C. Cernik and colleagues.The researchers concluded: ...
2009 NOV 24 ... and 46 had wedge or segmental resections. There were 30 primary hepatic and 46 metastatic tumor diagnoses. There were a total of 33 (43%) recurrences with a mean time to ...
2009 NOV 25 ... a study "To determine event free Survival (EFS) of children with Wilms tumor (WT) and metastatic liver disease at diagnosis Summary and Background Data: We reviewed patients with stage ...
2009 NOV 29 ... survival (PFS) or OS is the most appropriate endpoint in clinical trials of metastatic cancer, and to determine if it is reasonable to expect that treatment benefit in PFS ...
2009 NOV 24 ... In 2000, Iwata et al. [9] proposed a model which describes the evolution of an untreated metastatic tumors population. We provide here a mathematical analysis of this model which brings us ...
Subject: Discrete and Continuous Dynamical Systems
2009 NOV 23 ... by four percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease. "Since its approval, Avastin has garnered substantial patient ...
2009 NOV 23 ... select EGFRIs have been approved in certain patients with non-small cell lung cancer, metastatic colorectal carcinoma, and advanced squamous cell carcinoma of the head and neck. Various ...
2009 NOV 23 ... "This study was designed to investigate the prognostic significance of the metastatic lymph node ratio (MLR), which is calculated by dividing the number of...
2009 NOV 23 ... to be superior to tamoxifen in disease free survival (DFS) in the treatment of both metastatic and early breast cancers. While the data on side effects is limited, AI (compared to ...
2009 NOV 23 ... involved in differential IL-6 gene expression in breast cancer cells with different metastatic properties," researchers in Ghent, Belgium report. "In weakly...
2009 NOV 23 ... Biology and Medicine, "Paclitaxel is a chemotherapeutic agent used for the treatment of metastatic breast cancer. 2,5,7,8-Tetramethyl-2R-(4R, 8R-12-trimethyltridecyl) ...
2009 NOV 23 ... "Its TIL and TC expression are both associated with acquisition of an invasive and metastatic phenotype and may be a useful prognostic indicator." Sorrentino and ...
2009 NOV 23 ... 1. Our studies indicate that expression of the alpha 2 beta 1 integrin, a suppressor of metastatic breast tumor growth, is stimulated in breast tumor cells by an autocrine SEMA3A ...
2009 NOV 23 ... 0.80 to 1.0). In both N1 and N2 disease, a lower percentage of lymph nodes involved with metastatic disease was associated with improved survival (P < 0.0001). The increasing ratio of ...
2009 NOV 23 ... carcinomas, related to good outcome as optimal surgery becomes possible, and metastatic tumors associated with poor prognosis and a dramatic decrease in survival. In ...
2009 NOV 23 ... worldwide, Discovery of serum tumor markers could facilitate early NSCLC detection and metastatic prognosis. Here, we simultaneously analyzed the NSCLC cell secretome and proteomic ...
2009 NOV 23 ... subunit B (SDHB)-related PHEO/PGLs often present with aggressive and rapidly growing metastatic lesions. Currently, there is no proven effective treatment for malignant PHEO/PGLs." ...
2009 NOV 23 ... II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. As previously announced, having achieved the study-specified ...
2009 NOV 23 ... progressed well. The palifosfamide (ZymafosTM, ZIO-201) randomized Phase II trial in metastatic or unresectable soft tissue sarcoma achieved the study-specified efficacy milestone ...
